Malignancies clinical trials at UCLA
2 in progress, 1 open to eligible people
Extension Study for Patients Previously Enrolled in Studies with Pelabresib
open to eligible people ages 18 years and up
The purpose of this study is: 1. To provide continued pelabresib treatment to patients who have previously received pelabresib in a parent study and continue collecting safety and efficacy information 2. To evaluate the overall survival and leukemia-free survival of patients who discontinued placebo or pelabresib treatment in pelabresib parent studies
Los Angeles, California and other locations
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Sorry, in progress, not accepting new patients
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
Los Angeles, California and other locations
Our lead scientists for Malignancies research studies include Deborah Wong.
Last updated: